InvestorsHub Logo
Followers 183
Posts 25188
Boards Moderated 14
Alias Born 04/03/2002

Re: jedijazz post# 433

Monday, 05/06/2019 10:49:21 AM

Monday, May 06, 2019 10:49:21 AM

Post# of 1294
Excellent enhancement of the BIXT scientific team announced today with the addition of Juan Carlos Lopez-Talavera, MD, PhD who comes from a major biomedical industry background. There is no question that he will make great contributions for Bioxytran.

Note Dr. Lopez-Talavera's comments:

“In my professional career I have always gravitated toward working with novel mechanisms. “ said Dr. Lopez-Talavera. ”The opportunity at Bioxytran is so vast, because tissue oxygenation represents a true unmet medical need and represents a tremendous untapped opportunity to target both the Ischemic Stroke and, has future potential for Acute Respiratory Distress Syndrome (“ARDS”). BXT-25 has the unique ability to deliver oxygen through a small molecule which can be effective in extending the “golden hour” in stroke victims and potentially for tissue regeneration in ARDS victims. I am honored to be part of this team and look forward to advancing the science and creating partnerships or joint ventures that will grow this field of research.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIXT News